1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Autor: Saad, F., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N.D., Procopio, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Constans Schlurmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Liu, Y-Z., Poehlein, C.H., Desai, C., Del Rosario, P.M.D., Clarke, N.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S1160-S1160

157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Autor: Oya, M.¹ (AUTHOR), Armstrong, A.J.² (AUTHOR), Thiery-Vuillemin, A.³ (AUTHOR), Shore, N.⁴ (AUTHOR), Procopio, G.⁵ (AUTHOR), Arslan, Ç.⁶ (AUTHOR), Mehra, N.⁷ (AUTHOR), Parnis, F.⁸ (AUTHOR), Brown, E.⁹ (AUTHOR), Constans Schlurmann, F.¹⁰ (AUTHOR), Joung, J.Y.¹¹ (AUTHOR), Sugimoto, M.¹² (AUTHOR), Sartor, O.¹³ (AUTHOR), Liu, Y-Z.¹⁴ (AUTHOR), Poehlein, C.H.¹⁵ (AUTHOR), Desai, C.¹⁶ (AUTHOR), Del Rosario, P.M.D.¹⁶ (AUTHOR), Clarke, N.¹⁷ (AUTHOR), Saad, F.¹⁸ (AUTHOR)

Publikováno v: Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1495-S1495. 1p.